Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SEPRACOR R-ALBUTEROL PHASE II INTERIM RESULTS WILL BE PRESENTED

This article was originally published in The Tan Sheet

Executive Summary

SEPRACOR R-ALBUTEROL PHASE II INTERIM RESULTS WILL BE PRESENTED during the Nonprescription and Pulmonary-Allergy Drugs Advisory Committees' Nov. 14-15 meeting on the appropriateness of asthma therapies being available over-the-counter. Sepracor's single-isomer version of albuterol may become the "bronchodilator of choice for asthma therapy in both the Rx and OTC markets," the Marlborough, Mass.-based company speculated in a Nov. 9 press release announcing the issuance of a use patent (5,362,755) for the molecule. The Phase II trial of R-albuterol was initiated in Europe in mild asthmatics. Phase II/III trials are projected to begin in 1995.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083438

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel